Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 New Entrants companies in Ribociclib
by Most Patent Filing In 5 Years in the world in 2022

The Ribociclib top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filing In 5 Years Ribociclib New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Ontario, Canada
Patent: 4
2
Patent: 4
3
Patent: 4
4
Oncology,Medicine,Health care,
...[+2]
Patent: 3
5
Graduate degree,Academic Training,The Internet,
...[+2]
Patent: 3
6
Patent: 2
7
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Patent: 2
8
Patent: 2
9
Military science,Materials science,Academic achievement,
...[+2]
Patent: 2
10
Contract research organization,Health care,Liposome,
...[+2]
Patent: 2
11
Patent: 2
12
Noord-Brabant, Netherlands
Patent: 2
13
Patent: 2
14
Patent: 2
15
Tel Aviv, Israel
Gastrointestinal agent,Immunotherapy,Clinical trial,
...[+2]
Patent: 2
16
Active ingredient,Radioimmunoassay,Diagnostic microbiology,
...[+2]
Patent: 1
17
Patent: 1
18
Patent: 1
19
Olaris, Inc.
Substance abuse,Health care,Biotechnology,
...[+2]
Patent: 1
20
New Ventures,Medicine,Health care,
...[+2]
Patent: 1
Page generation time: Jul 07 2025